Global approvals ROIS is approved by major international authorities including FDA, EMA, ANVISA, PMDA, and KFDA, enabling access to a broad global customer base and potential for expanded cross-border CDMO services in vaccines, biologics and aseptic fill-finish.

Expanded capacity With 12 injectable filling lines (PFS and Vials) and end-to-end manufacturing capabilities from scale-up to packaging, ROIS can support large- and mid-scale partnerships for aseptic fill-finish, secondary packaging, serialization, and testing needs.

Strategic asset move Recent asset investment and the Phoenix, Arizona plant acquisition activity indicate ROIS is expanding manufacturing footprint in the US, creating nearshore or onshore options for North American vaccine and biologics customers.

Leadership addition New Chief Commercial Officer appointment signals a focus on accelerating business development, market expansion, and customer-facing strategies to capture opportunities in injectable fill-finish, biologics, and lyophilized products.

Industry fit Specialization in vaccines, mAbs, mRNA and oligonucleotides, combined with WFI dossier capabilities and secondary packaging expertise, positions ROIS to address high-value, complex biologics programs and regulatory-driven projects for biotech sponsors.